News ADA: Novo continues effort to rehabilitate CagriSema Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.
News Could a Novo error set up early GLP-1 generics in Canada? Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
News Novo Nordisk teams up with NVIDIA on AI models Novo Nordisk and tech giant NVIDIA have joined forces on a new project that aims to speed up drug discovery using generative AI.
News Novo Nordisk obesity drug linked to rare cause of sight loss The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
News NHS cleared to use Novo Nordisk's long-acting growth hormone Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.
News MHRA advises contraception for women taking 'skinny jabs' Women in the UK taking weight-loss injections have been warned by the MHRA that they should make sure they are using effective contraception.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
